Johnson & Johnson topped Q2 earnings expectations on Tuesday, but the company stock toppled on its trimmed profit outlook. On today’s stock market, JNJ stock rose fell 1.5% to 171.69, according to observers this could be attributed to the overall strength of the US dollar during Q2.
The best performance came out of J&J’s pharmaceuticals division where sales climbed 6.7% on a strict, as-reported basis to $13.32 billion.
Overall, the health care giant reported adjusted earnings of $2.59 a share on sales of $24.02 billion in the second quarter. Analysts polled by FactSet expected J&J to earn $2.54 a share on $23.77 billion in sales. On a year-over-year basis, earnings rose 4% while sales climbed 3%.
That reading narrowly topped forecasts. Psoriasis treatment Stelara and cancer drug Darzalex were bolstered as strong performers. The company also reported unexpected strength for its one-shot Covid vaccine, which brought in nearly double what analysts expected. Sales were $544 million vs. forecasts for $278 million.
The two key drivers of upside were Covid vaccine sales $266 million above consensus and Darzalex sales $168 million above. The two key shortfalls vs. consensus were Imbruvica $130 million below and pulmonary hypertension (treatments) $74 million below.<\/p>\n","protected":false},"excerpt":{"rendered":"
Johnson & Johnson topped Q2 earnings expectations on Tuesday, but the company stock toppled on its trimmed profit outlook. On today’s stock market, JNJ stock rose fell 1.5% to 171.69, according to observers this could be attributed to the overall strength of the US dollar during Q2. The best performance came out of J&J’s pharmaceuticals …<\/p>\n","protected":false},"author":13,"featured_media":44351,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39,36],"tags":[7113,7825],"class_list":["post-68727","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-global-stock-markets","category-market-updates","tag-earnings","tag-johnson-johnson"],"_links":{"self":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts\/68727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/comments?post=68727"}],"version-history":[{"count":2,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts\/68727\/revisions"}],"predecessor-version":[{"id":68731,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/posts\/68727\/revisions\/68731"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/media\/44351"}],"wp:attachment":[{"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/media?parent=68727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/categories?post=68727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/noortrends.ae\/en\/wp-json\/wp\/v2\/tags?post=68727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}